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16ResearchAttention-deficit hyperactivity disorder (ADHD) 
and glial integrity: S100B, cytokines and 
kynurenine metabolism - effects of medication
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Abstract
Background: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their 
display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial 
supply of energy to support neuronal activity.
Method: We pursued one test of the idea with measures of a neurotrophin reflecting glial integrity (S100B) and the 
influences of 8 cytokines on the metabolism of amino-acids, and of tryptophan/kynurenine to neuroprotective or 
potentially toxic products that could modulate glial function. Serum samples from 21 medication-naïve children with 
ADHD, 21 typically-developing controls, 14 medicated children with ADHD and 7 healthy siblings were analysed in this 
preliminary exploration of group differences and associations.
Results: There were no marked group differences in levels of S100B, no major imbalance in the ratios of pro- to anti-
inflammatory interleukins nor in the metabolism of kynurenine to toxic metabolites in ADHD. However, four trends are 
described that may be worthy of closer examination in a more extensive study. First, S100B levels tended to be lower in 
ADHD children that did not show oppositional/conduct problems. Second, in medicated children raised interleukin 
levels showed a trend to normalisation. Third, while across all children the sensitivity to allergy reflected increased 
levels of IL-16 and IL-10, the latter showed a significant inverse relationship to measures of S100B in the ADHD group. 
Fourthly, against expectations healthy controls tended to show higher levels of toxic 3-hydroxykynurenine (3 HK) than 
those with ADHD.
Conclusions: Thus, there were no clear signs (S100B) that the glial functions were compromised in ADHD. However, 
other markers of glial function require examination. Nonetheless there is preliminary evidence that a minor imbalance 
of the immunological system was improved on medication. Finally, if lower levels of the potentially toxic 3 HK in ADHD 
children were confirmed this could reflect a reduction of normal pruning processes in the brain that would be 
consistent with delayed maturation (supported here by associations with amino-acid metabolism) and a reduced 
metabolic source of energy.
Background
Childhood attention-deficit/hyperactivity disorder
(ADHD) is characterised by poor attention-related abili-
ties, restless activity along with cognitive and behavioural
impulsivity. All 18 features of the diagnosis are prefaced
by the word "often" in the DSM-IV. Such variability is also
typical of laboratory measures of the children's abilities,
and is well illustrated by response times (RTs) in neurop-
sychological tests for all subgroups [1-3]. Thus, a core
feature of childhood ADHD is the variability of the nature
and timing of behavioural responses. This variability, typ-
ically measured on RT tasks, is a good candidate for an
endophenotype of the disorder [4,5]. A seminal hypothe-
sis was proposed to explain a potential biological basis for
this phenomenon [6]. In essence, these authors suggested
that the ability to sustain the rapid neuronal firing under-
lying responsivity requires the maintenance of the supply
of energy (the lactate shuttle) from the supporting glial
cells (the astrocytes). A deficient energy supply could
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Page 2 of 14result in the disruption of responsivity seen as variable
on/off responding in ADHD.
This pilot study examines levels of the cytokine-related
neurotrophin S100B as a putative biomarker of the integ-
rity of glial function, hypothesising that altered levels
could reflect dysfunction and an impaired energy supply
for neuronal activity. Serum S100B levels correlate
strongly with CSF measures [7] and they largely, but not
exclusively, derive from astrocytes and oligodendrocytes
[8]. S100B is involved in the regulation of glutamate and
calcium uptake, neuronal plasticity, energy metabolism
and in various neurodevelopmental processes [9], espe-
cially those involving the neurotrophic role of serotonin
(5-HT: [10]). Over production of S100B (micromolar lev-
els) can be toxic and follow brain-damage resulting from
stroke and ischemia [11] and accompany severe mental
disorders such as schizophrenia, bipolar disorder, depres-
sion, Alzheimer's disease, Down's syndrome, phenylketo-
nuria and cerebral palsy [12-15]. In some of these
disorders variability features strongly [6,16].
However, in cell culture prolonged glucose deprivation
can down-regulate S100B mRNA expression and eventu-
ally lead to reduced S100B release [17]. A regional reduc-
tion of S100B levels has also been reported in rats
subjected to prenatal stress [18]. In brain slices reduced
S100B secretion has been associated with high levels of
potassium ions [19]. Indeed, high levels of potassium are
a prediction of Russell's hypothesis on deficient energy
supplies in ADHD [6]. As ADHD is a disorder with quali-
tative and quantitative differences from severe mental ill-
ness such as the psychoses, we hypothesised that levels of
the cytokine may be reduced reflecting inefficient control
of the energy supply to active neuronal pathways.
Markers of one of the potential causes of glial dysfunc-
tion were also sought. These markers reflect the nature of
tryptophan metabolism. From 80 to 95% of brain levels of
l-tryptophan are metabolised in the kynurenine pathway
with the remainder contributing to the synthesis of 5-HT
[20]. Activity in these two pathways merits attention for
two reasons. First, there is good reason to believe that
levels of 5-HT activity in ADHD are anomalous [21-23].
Second, catabolic products of kynurenine can be neuro-
protective (Kynurenic acid, KA, a glutamate antagonist)
or potentially neurotoxic (3-OH-Kynurenine, 3HK, a glu-
tamate agonist:[24]), where 3HK is a precursor to the
production of toxic quinolinic acid. Alternatively this
metabolic pathway could be considered a step in the pro-
duction of nicotine adenine dinucleotide (NAD) as a
source of energy for neuro-glial networks. Clearly
unusual levels of these substances could be indicative of
factors influencing anomalous glial function.
Finally, an important determinant of the production of
glial kynurenine and its metabolites is the activity of the
indoleamine and tryptophan 2, 3-deoxygenases (IDO and
TDO). The activity of these enzymes is modulated in part
by the balance between pro- and anti-inflammatory
interleukins. An imbalance would also provide evidence
for or against anomalous kynurenine metabolism and
glial function. Altered ratios of the interleukins and
kynurenine metabolism have indeed been described for
depression and bipolar illness [25-27].
The proinflammatory cytokines suitable for measure-
ment include the interleukins IL-1β, IL-2, IL-6, tumour
necrosis factor-α (TNF-α) and interferon-gamma (IFN-γ)
for contrast with the antiinflammatory cytokines IL-10
and IL-13 [28]. Also included in the analyses were IL-4
(where levels proved to be below detection limits) and IL-
16 that stimulates proinflammatory cytokine production
but has been reported also to have antiinflammatory
properties in different disorders. We are aware of only
one early report on interleukin levels in childhood disor-
ders (IL-2, IFN-γ, IL-4, IL-5, IL-10, and TNF-α). In CSF
samples from patients with childhood onset of obsessive
compulsive disorder, ADHD and schizophrenia there was
a skew towards type-1 interleukins in the former, a pre-
ponderance of type-2 in the latter disorders with values
from the ADHD patients being intermediate [29]. How-
ever, there are suggestions from genetics' studies that
alterations in the interleukin balance could contribute to
ADHD. The gene for the IL-1 receptor (IL-1Ra) can have
2 or 4 repeats. An initial study of 86 children with ADHD
and their parents showed that transmission of the former
was associated weakly with a decreased risk, and of the
latter with an increased risk of transmission [30]. But, a
second study of 179 families could not replicate this
result [31]. A further study of IL-6 reported a marginal
preponderance of the C-allele in ADHD and that an asso-
ciation was noted with the DRD2 Taq1A allele in those
children who responded to methylphenidate treatment
[32]. A recent genome wide scan of 958 ADHD child-par-
ent trios reported that 2 single nucleotide polymorphisms
(SNPs) in the IL-16 gene were associated with the inat-
tentive phenotype, and a second analysis of 930 patients
described a nominal association for IL-3 (NFIL3: C allele)
with an earlier onset of the disorder [33,34]. The results
of these interleukin studies are equivocal, but provide
indications of a disturbance that merits closer examina-
tion.
Lastly, our analysis included a number of amino acids
not only as a control for the tryptophan measures, but
because branched-chain amino acids can provide an
alternative energy supply to neurons. Amino acids such
as leucine, isoleucine and valine can be broken down in
glial cultures to metabolites that can enter the tricarbox-
lic acid cycle directly or even produce lactate itself [35-
37].
In summary, we report on a pilot study of serum sam-
ples from medication-naïve children with and without
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S100B, 2) tryptophan metabolites, 3) 17 amino-acids, and
4) a set of pro- and antiinflammatory interleukins as
potential indicators of the integrity of glial cell function
(hypothesis 1: decreased in ADHD), of the presence of
toxic over-protective features of amino-acid metabolism
(hypothesis 2: in ADHD) and the immunological activity
influencing metabolism (hypothesis 3: an imbalance). A
high variability of RT (coefficient of variance) for children
with ADHD was established on a continuous perfor-
mance task (CPT) prior to entry to the study.
Methods
Subjects
Participants included 21 medication-naïve children
referred consecutively to the Clinic for Child and Adoles-
cent Psychiatry in Essen who were given a DSM-IV diag-
nosis of ADHD combined type. A second older group of
14 children for whom the same diagnosis had been made
4 years previously and were receiving medication were
also recruited (ADHDmed). One was receiving atomox-
etine, one Ritalin and the others a retard formulation
(Concerta or Medikinet, 30-40 mg). A control group
(CON) of 21 typically developing children for the ADHD
group was recruited by advertisement. An attempt to
recruit controls for the ADHDmed group from their
healthy siblings resulted in only 7 participants (SIBS).
The gender, age, IQ, and body-mass index (BMI) of the
children, and the socio-economic status of the father are
shown in table 1. In accord with the Declaration of Hel-
sinki, the protocol for the study was approved by the eth-
ics committee of the University Medical Faculty: parents
and children received verbal and written information and
gave written consent to the procedures.
A research diagnosis was made using a semi-structured
parent interview (Parental Account of Children's Symp-
toms/PACS:[38,39]). Information was collected from the
parent about the child's behaviour relating to 4 domains:
mood disorder, ADHD/hyperkinetic disorder, disruptive
behaviour and additional problems. Parents describe
their child's behaviour in unstructured (e.g. playing
alone), semi-structured (e.g. meal times) and structured
(e.g. homework) daily life situations. The severity and fre-
quency of the behaviour are rated according to previously
defined criteria. The replies are coded on a 4-point scale
for the previous week and the previous year (in an
unmedicated state) on the basis of formal training and
written definitions. A standardized diagnostic algorithm
based on the DSM-IV criteria relating to symptoms, age
of onset, situational pervasiveness and clinical impair-
ment was applied. Previous studies have shown high
inter-rater reliability with correlations between .76 and
.96 [39]. Symptoms were also rated with the long forms of
the Conners parent and teacher ratings scales (CPRS-R:
L, CTRS-R: L, scales with 80 and 59 items, respectively:
[40]). Five subscales were considered for analysis: opposi-
tion, anxiety, inattention, hyperactive-impulsive and the
total overall ratings. The extent of comorbid internalizing
and externalizing problems was represented by the num-
ber of children scoring T > 65 on anxiety/oppositional
scales of either the CTRS or CPRS: 9/14 (ADHD), 6/2
(CON), 6/9 (ADHDmed) and 3/1 (SIBS). Exclusion crite-
ria included a history of encephalitis, autism, epilepsy,
Tourette syndrome, bipolar disorder, IQ < 80, brain dam-
age and any genetic or medical condition associated with
externalizing behaviours that might mimic ADHD.
In addition, the nature of any allergy, current or past
and its severity (0-3) was also recorded. The IQ was
assessed with the standardized version of the CFT-20-R
[41] or for subjects younger than 9 years the Kaufman
assessment battery for children [42]. The high variability
of RT (coefficient of variance) and performance (errors)
for children with ADHD was established on a CPT and
constituted a criterion for entry into the study. The asso-
ciation of these results with the biochemical measures are
the subject of an associated report [43].
Biochemical analyses
Fasting venous blood (20 ml) was withdrawn in the
morning (08:00-09:00), the serum separated and stored at
-80°C for later analysis by technicians blind to the source
of the sample [44]. S100B concentrations were measured
in the serum by an immuno-luminometric assay that
detects the heterodimer S100 A1B and the homodimer
S100 BB (ELECSYS S100™, Roche Diagnostics, Switzer-
land). The lowest detectable concentration of S100B was
0.02 μg/L. Intra- and inter-assay coefficients of variation
were < 5% and < 8%, respectively.
The cytokines IFN-γ, IL-1β, IL-2, IL-3 IL-6, IL-10, IL-
13, IL-16, LIF, and TNF-α were analysed in the serum
using ELISA test kits from R&D systems as described in
the manufacturer's instruction. For determination of IL-
1β, IL-6, IL-10 and TNF-α we used high sensitive assays.
All samples were below the detection limit for leukaemia
inhibitory factor (LIF: limit: 7.8 pg/ml), and IL-3 (limit:
15.6 pg/ml), and for 40/63 samples IL-1β (detection limit:
0.063 pg/ml) was not detected. These samples were
excluded from further calculation.
For amino acid determination the AccQ Tag method
was used (Waters Corporation, Milford, MA, USA). This
analysis concerned the 5 tryptophan-competing amino
acids (isoleucine, leucine, phenylalanine, tyrosine and
valine) and 12 other amino-acids (alanine, arginine,
aspartate, glutamate, cystine, glycine, histidine, lysine,
methionine, proline, serine and threonine). Briefly, after
pre-column derivatization using 6-aminoquinolyl-N-
hydroxy-succinimidyl carbamate, the samples were
injected to a HPLC system consisting of a 2695 separa-
Oades et al. Behavioral and Brain Functions 2010, 6:29
http://www.behavioralandbrainfunctions.com/content/6/1/29
Page 4 of 14tions module connected to a 2475 fluorescence detector
(Waters). The gradient used the AccQ Tag eluent, ace-
tonitrile, and HPLC grade water with a flow rate of 1.0
ml/min at a temperature for the AccQ Tag column (3.9 ×
150 mm) of 37°C. The detection wave lengths were λex =
250 nm and λem = 395 nm.
For tryptophan, kynurenine and their metabolites the
analytes were extracted from samples and calibrators/
controls using Waters Oasis MCX 1 cc (30 mg) extraction
cartridges. The eluent was evaporated to dryness under
nitrogen and reconstituted with 150 μl 0.1 M PBS. Recon-
stituted samples/calibrators/controls were transferred to
microinjection vials and the analyses run on a Waters
2695 chromatograph connected to a Waters Model 2487
dual-l UV detector and a 2475 fluorescence detector. For
determination of 5-HIAA, kynurenine, KA and 3HK, 100
μl of the samples were loaded onto a 250 mm × 4 mm
Supersphere 60 RP-select B, C8 column (Merck, Darm-
stadt, Germany). Due to the relatively higher concentra-
tion, a second 10 μl injection was performed for the
determination of tryptophan. The gradient elution used a
mobile phase consisting of a mixture of 0.05 M sodium
acetate (solvent A: pH 4.80; solvent B: pH 3.65), ace-
tonitrile (solvent C), and methanol (solvent D). The flow
rate was 0.80 ml/min with the column temperature set to
35.0°C, while the samples were cooled to 4.0°C. Trypto-
phan (lex: 300 nm; lem: 350 nm) and 5-HIAA (lex: 300
nm; lem: 340 nm) were measured by fluorescence detec-
tion; kynurenine (365 nm), KA (330 nm), and 3-HK (365
nm) were measured by UV detection. Run times after
injection until detection of the compounds were about
20.4 min for tryptophan, 13.4 min for kynurenine, 22.5
min for KA, and 7.0 min for 3HK. Data were processed
using EMPOWER for Windows 2000 software (Waters).
The concentrations were established through comparison
of peak heights of the single analytes with the peak
heights of the respective calibration curves.
Three indices of activity in the tryptophan metabolic
path were calculated from the above serum analyses. (1)
The tryptophan availability index, 100 × tryptophan/sum
of the competing amino acids; (2) The tryptophan break-
down index that reflects the sum of the activities of the
TDO and ID enzymes, kynurenine/tryptophan, and (3a)
the neuroprotective index, KA/3HK. It may be noted that
neuroprotection would be increased with a larger index
value. This third index differs from that used by Myint et
al. [44] who calculated the ratio of 1000 × KA/kynure-
nine, which will be referred to here as index 3b that repre-
sents the turnover rate within the neuroprotective
pathway and does not refer directly to the production of
toxic metabolites.
Data analysis
The groups were compared on demographic data and
behavioural ratings (questionnaire and biochemistry)
with the use of ANOVA for continuous variables and the
Table 1: Characteristics of the subject groups (means with standard deviations, SD, and range of values) and the serum 
concentrations of S100B (pg/ml)
N Gender 
m/f
Age 
years
IQ BMI Allergy 
severity
SES F-c S100B 
(pg/ml)
ADHD 21 14/7 8.84 95.8 16.5 0.86 4.3 93.89
SD (1.4) (10.7) (2.4) (1.2) (2.2)# (17.63)#
Range 6.6-11.7 82-124 13.9-24.8 0-3 Np8 Nc1 1-7 70-152
CON 21 20/1 11.0 114.1 17.9 0.76 3.5 97.21
SD (1.5) (14.4) (3.1) (0.9) (2.1) (31.38)#
Range 7.7-13.4 92-141 13.5-24.9 0-3 Np11 Nc 1 1-7 55-156
ADHDmed 14 12/2 12.6 106.7 20.5 0.29 4.1 84.08
SD (2.1) (12.4) (4.6) (0.7) (1.9) (26.67)
Range 7.9-15.5 92-134 14.2-32 0-2 Np2 Nc 0 2-6 35-127
SIBS 7 4/3 11.7 108.1 18.5 0 4.4 96.86
SD (2.1) (14.0) (2.5) (0) (2.0) (34.01)
Range 9.0-14.4 87-134 15.6-23.1 0 Np0 Nc0 2-6 59-153
ADHD, children with attention deficit hyperactivity disorder (combined type); CON, healthy controls; ADHDmed, replication group of children 
with ADHD (medicated), SIBS, siblings without medication; BMI, body-mass index; SES, current socio-economic status of the father (F-c: scale 
1-7 for professions:[100]), # N = 19. Allergy severity refers to past and current experience (scale 0-3) affecting Np individuals in the past (>12 
months) or Nc individuals currently. There were more females in the ADHD and SIB groups (p < 0.05). The ADHD group was younger and had 
a lower IQ than the other 3 groups (Scheffe p < 0.007) but did not differ significantly on BMI, allergy or SES.
S100B levels omit as outlier values one CON (248 pg/ml) and one ADHDmed measure (385 pg/ml) which were > 3 SD above the mean.
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after controlling for age, BMI, gender and allergy. The
covariates in the final analysis are noted in the results sec-
tion, and are usually restricted to age/gender as the sig-
nificant correlates. (Age proved to be a good proxy for
BMI in the absence of overweight cases.) Homogeneity of
variance was usually evident where the larger subject
groups were examined (Levene's test). The analyses con-
sider separately S100B, the interleukins, the amino aids
and kynurenine metabolites. Pearson correlations
between biochemical measures were computed and,
being of an exploratory nature, are reported uncorrected.
Nonetheless, P values are 2 tailed and unless otherwise
stated partial correlations that controlled for age or gen-
der are cited. The significance of the reported tests at α =
5% can be assessed against a rough false discovery rate
(FDR) criterion of p ≤ 0.02. Values up to α = 10% (FDR: p
≤ 0.05) are noted as trends or tendencies.
Results
S100B
Group characteristics and the mean serum concentra-
tions of S100B are given in table 1. Overall there were no
significant correlations of S100B levels with age, BMI, IQ,
allergy severity or SES. S100B levels were marginally
lower in the ADHD group but did not differ significantly
from the CON group even after controlling for the vari-
ance due to gender, age and BMI. The slightly lower
S100B levels in the medicated group did not differ signifi-
cantly from the others. Contrasting all ADHD children
with those without the diagnosis showed no differences
in the ANCOVA (89.9 vs. 97.1 pg/ml: F(1,54) = 1.49, p =
0.23, η2 = 0.03).
We then examined whether the severity or nature of the
symptoms influenced levels of S100B. Using the norm T-
values for the sub-scales of the Conners' ratings to con-
trast ADHD- and control children with high (T ≥ 65, n =
16) and low (T ≤ 50, n = 12) total DSM or inattentive
DSM CPRS ratings showed there were no differences in
the levels of S100B. However, across all children the
CPRS ratings of anxiety (not inattention or opposition)
showed a weak bivariate tendency to relate to S100B lev-
els (n = 56, r = +0.23, p < 0.09). Indeed, on a closer exami-
nation the presence of internalizing symptoms
contributed to the relationship of decreasing S100B levels
with increasing DSM total symptom ratings in the ADHD
and the combined ADHD groups. In both instances the
partial correlations for anxiety controlling for ratings of
oppositionality approached significance (df 15/27, r = -
0.54/-0.43, p = 0.027/0.020). A similar relationship was
not evident for other ratings (e.g. inattention) or for the
controls.
In summary, independent of age, BMI and gender there
were no group differences in the level of serum S100B
between those with and without a diagnosis of ADHD.
However, S100B levels were lower in those children
expressing higher levels of non-externalizing symptoms
(e.g. mood, anxiety).
Tryptophan metabolism
Comparison of the measures of tryptophan and 5 com-
peting amino acids in 4 subject groups, showed a trend
for higher levels of tryptophan alone in the ADHD sub-
jects independent of medication (table 2: F(3,55) = 2.56, p
= 0.06, covariates age and gender). This was confirmed in
the comparison of combined ADHD vs. combined con-
trol groups (F(1,57) = 5.36, p = 0.02, η2 = 0.09, power 0.62:
covariates age and gender). Controlling for BMI or allergy
marginally attenuated the significance (F = 3.3). ANCOVAs
(age, gender) for tryptophan availability and breakdown
confirmed higher and lower levels (respectively) in the
combined ADHD than in the control groups (F(1,58) =
2.97/4.93, p = 0.09/0.03, η2 = 0.05/0.08, power 0.40/0.59,
respectively: table 2). Levels of the 5 competing amino
acids did not differ between groups.
Even though levels of kynurenine rose with increasing
age (n63, r = +0.30, p < 0.02) it is notable that the levels of
metabolites in the two different pathways for tryptophan
breakdown (kynurenine and 5-HIAA) did not differ
between groups with or without controlling for age, gen-
der or BMI. However, the tendency for lower 3HK levels
in the ADHD groups than in the controls (F(1,58) = 3.15,
p = 0.08) merited closer attention: the same trend was
evident in the neuroprotection 3a index that contrasts the
KA/3HK pathways (F = 1.86; but not index 3b that
reflects kynurenine/KA turnover, F = 0.03). Partial corre-
lations (accounting for age and BMI) showed, as
expected, a strong relationship for tryptophan with
kynurenine (but not 5-HIAA) in ADHD, ADHDmed and
control groups (r = +0.51-0.83, p = 0.02-0.001). But, in
contrast to the relationships between kynurenine and the
neuroprotective KA in all groups (r = +0.41-0.73, p =
0.09-0.007), the relationship of kynurenine to the toxic
metabolite 3HK was marked in the controls (r = +0.85, p
< 0.000), and absent in the ADHD group (p = 0.35). Med-
ication partially restored the association in ADHDmed
children (p = 0.01).
In summary, there was a tendency for ADHD children
to show higher levels of tryptophan and tryptophan avail-
ability than those without ADHD. While associations of
tryptophan levels with the 5-HT metabolite were not evi-
dent in any group, kynurenine breakdown was biased
towards the potentially toxic 3HK in the control group
alone (cf. hypothesis 2).
Other amino-acids
Most of the 17 amino-acids studied showed non-signifi-
cantly higher concentrations in the ADHD than the con-
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isoleucine, cystine, methionine and proline (figure 1).
Concentrations decreased significantly with age (ADHD
and CON vs. ADHDmed and SIBS) for histidine and ser-
ine (F(3,56) = 4.4-6.1, p = 0.001-0.007, η2 = 0.19-0.25): sig-
nificance levels were reduced with age as a covariate.
Only glycine showed elevated levels in the ADHD group
compared to each of the other groups (F(3,56) = 3.29, p =
0.028, η2 = 0.15), although, noting the medium effect size,
phenylalanine showed a descriptively similar trend with
age as covariate (F(3,55) = 2.27, p = 0.09, η2 = 0.11).
We explored bivariate correlations of the levels of
amino-acids with cytokines in ADHD and control
groups. The following two patterns emerged with partial
correlations accounting for age. First, in controls S100B
levels correlated positively with those for valine, leucine
and isoleucine (r = +0.5, p < 0.04), methionine and threo-
nine (r = +0.6, p < 0.02). But, in the ADHD group there
was only a minor negative relationship with proline (r = -
0.5, p = 0.05: note that here proline was positively corre-
lated with IL-10, r = +0.6, p = 0.025). Second, in controls
there were negative relationships for the antiinflamma-
tory IL-13 with arginine (r = -0.70, p = 0.017) and the
proinflammatory IL-6 with cystine (r = -0.48, p = 0.03). In
contrast, the only associations for the ADHD group were
that proinflammatory TNF-α levels tended to be posi-
tively related to those for alanine (r = +0.55, p = 0.029)
and glutamate (r = +0.5, p = 0.05).
Exploring the correlations for amino-acid levels with
kynurenine metabolism strikingly different patterns for
each subject group emerged. (1) CON: 6 amino-acids
correlated strongly and exclusively with kynurenine and
3HK: (Kynurenine: Val, Phe, Leu, Ile, Lys r = +0.6-0.7, p =
0.001, Met r = +0.45, p = 0.035: 3HK: r = + 0.49-0.59, p =
0.024-0.005). (2) ADHD: correlations were restricted
entirely to the neuroprotective index for Thr and Met (r =
+0.47/0.57, p = 0.04/0.01). (3) ADHDmed: 12 amino-
acids correlated positively with kynurenine and 10 corre-
lated negatively with the tryptophan breakdown index
and with no other item: (Kynurenine: Val, Phe, Leu, Ile,
Arg, Lys, Met, r = +0.61-0.71, p = 0.02-0.005; Ala, Glu,
Gly, Ser, Thr, r = +0.57-0.59, p = 0.025-0.04: Try-break-
down index: Val, Phe, Leu, Ile, Ala, Met, r = -0.67 to -0.79,
p = 0.001-0.008; Tyr, Arg, Glu, Lys, r = -0.5 to 0.66, p =
0.07-0.01).
In summary, amino-acid concentrations were related
differentially with cytokine levels and kynurenine metab-
olism in each subject group. First S100B levels related to
some amino-acids in control but not ADHD children.
Second, a few amino-acids were related to a proinflamma-
tory cytokine in the ADHD group in contrast to the nega-
tive relationship seen in the controls. Striking is that
many amino-acids related to kynurenine and its toxic
Table 2: Mean levels of tryptophan, metabolites and indices of the relative activity at 3 metabolic stages in 4 subject 
groups (SD in parentheses)
Group
N
ADHD
20/21
CON
19/21
ADHDmed
14
SIBs
7
Tryptophan *
μg/ml
11.82
(2.16)
10.78
(2.23)
12.49
(2.69)
11.84
(2.55)
Availability *
Index
12.75
(3.49)
11.56
(2.14)
13.51
(1.72)
13.10
(0.60)
Kynurenine
ng/ml
629.5
(98.5)
634.5
(132.3)
629.9
(83.3)
628.0
(85.1)
Breakdown#
Index
0.054
(0.009)
0.060
(0.012)
0.051
(0.006)
0.054
(0.009)
Kynurenic acid
ng/ml
8.06
(2.08)
8.42
(3.25)
9.08
(2.17)
8.51
(2.50)
3OH-Kynurenine #
ng/ml
18.41
(4.43)
20.69
(5.05)
19.34
(3.66)
19.40
(3.65)
Neuroprotection
Index A (KA/3HK)
0.457
(0.139)
0.414
(0.141)
0.469
(0.071)
0.437
(0.085)
Neuroprotection
Index B (TR)
12.93
(3.038)
13.52
(4.961)
14.34
(2.624)
13.57
(3.772)
5-HIAA
ng/ml
12.08
(3.84)
11.84
(5.31)
13.97
(6.61)
13.79
(5.93)
Combined ADHD groups vs. controls * p < 0.02, # p < .08 where kynurenine levels related to 3HK in controls (r = +0.85, p < 0.000), and not in 
the ADHD group (p = 0.35).
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(above) for marked catabolic activity in healthy children.
This was not evident in the ADHD group. Medication
was associated first with a reinstatement of amino acid
associations with kynurenine levels, and secondly
decreasing amino acid levels were inversely related to the
tryptophan breakdown index.
The cytokines
Six of the 8 interleukins measured showed non-signifi-
cantly higher levels in the ADHD than control groups:
only the small number of proinflammatory IL-1β mea-
sures was lower in ADHD children. TNF-α levels were
similar in ADHD and CON groups (table 3). All these
trends were reversed in the ADHDmed group. (Sibling
data are shown for completeness, but there were too few
data for analysis.) The medication effect approached sig-
nificance for IFN-γ (F(1,24) = 3.43, p = 0.07, η2 = 0.13)
and for IL-13 (F(1,20) = 3.73, p = 0.07, η2 = 0.16) after
controlling for age and gender with quite strong effect
sizes in both comparisons.
IL-16 levels did not differ significantly between control
and ADHD groups (F = 0.62). But across all subjects IL-
16 levels correlated positively with the severity of allergy
(r = +0.26, p = 0.04, n = 61). Such a relationship was also
seen for the antiinflammatory IL-10 (r = +0.28, p = 0.03, n
= 58). The IL-16 relationship was not significant for any
group alone: but, there were indications of a possible
association with oppositional and hyperactive symptoms
(r = +0.22, p = 0.089/0.099) rather than the inattentive
ratings implicated in the genetic study (see introduction).
This association was reduced in a partial correlation con-
trolling for allergy severity. Interestingly, there were posi-
tive and negative partial correlations respectively for IL-
16 and IL-10 levels with those for S100B (r = +0.47, p =
0.07, r = -0.63, p = 0.01) in the ADHD, but not in the con-
trol groups.
The ratios of pro- to antiinflammatory interleukins
provide indices of the balance that influences enzyme
activity in the kynurenine metabolic pathway (hypothesis
3). For example, the ratio of proinflammatory TNF-α to
antiinflammatory IL-13 (but not IL-10) showed a trend
for low ADHD values (ADHD 0.27, SD 0.10; CON 0.35, SD
0.12) to increase on medication (ADHDmed 0.31, SD 0.06:
F(2,29) = 3.1, p = 0.06, η2 = 0.18, covariates age and gen-
der). However, the ratios of proinflammatory IL-2 and IL-
Figure 1 Mean serum concentrations (pmol/μl) of 17 amino acids for 4 groups of children (ADHD left and Controls right black column; AD-
HDmed left and Sibs right grey columns). Note the different scales in figure A (left) and B (right).
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fer between groups. In contrast, the low levels of the
proinflammatory IFN-γ to antiinflammatory IL-13 ratio
(but not IL-10) in the ADHDmed versus the ADHD
group (CON 0.69, SD 0.21; ADHD 0.60 SD 0.19; ADH-
Dmed 0.36, SD 0.11: F(1,21) = 11.76, p = 0.003) were
attenuated with the same covariates (F(1,19) = 3.70, p =
0.07, η2 = 0.16), suggesting a partial contribution of the
age and gender differences. Lastly, despite relatively few
data, the ratios of IL-1β to IL-10, IL-13 and IFN-γ were
lower in the ADHD than the control group and increased
in the ADHDmed children (F(2, 8-17) = 3.5-5.5, p = 0.05-
0.02, η2 = 0.29-0.54: e.g. IL-1b/IL-10, CON 0.45, SD 0.41;
ADHD 0.21, SD 0.14; ADHDmed 0.72, SD 0.81).
IL-16/IL-10 ratios were of interest because of the rela-
tionship to allergic sensitivity. Compared to controls they
were non-significantly lower in the ADHD and higher in
the medicated group (respectively, 184 SD 140, 199 SD 141
and 265 SD 299: F(2,46) = 1.18, p = 0.32, η2 = 0.05). How-
ever, the ratio correlated positively with CPRS ratings of
oppositional behaviour after controlling for age (r =
+0.57, p = 0.03). The correlation was reduced after con-
trol for allergic sensitivity and was absent in the ADH-
Dmed group (r = -0.08).
Figure 2 shows correlations between levels of the cytok-
ines (p = 0.05-0.001). The figure illustrates (in bold) the
associations between TNF-α, IFN-γ and IL-13 that were
significant and common to each of the main groups
(ADHD, ADHDmed and CON). It also shows (broken
lines) that there was a further relationship unique to each
group.
In summary medication tended to normalise mild alter-
ations of cytokine levels in ADHD children. The ratio of
TNF-α/IFN-γ, lower in ADHD than control children,
Table 3: Mean levels of cytokines (pg/ml, with standard deviations [SD]) for four subject groups
A
Group
ADHD
(SD)
CON
(SD)
ADHDmed
(SD)
SIBS
(SD)
IL-1β 0.23 0.35 0.62 1.25 F(2,17) = 1.30, p = 0.29.
0.30 0.30 0.67 1.39
(N): (7): (7): (7): (2):
IL-2 7.47 6.58 6.96 6.15 F(2,40) = 0.16, p = 0.86
3.58 2.96 3.39 3.19
(N): (17): (16): (11): (4):
IL-6 1.02 0.89 0.87 1.06 F(2,50) = 0.74, p = 0.48
0.64 0.60 0.66 0.61
(N): (20): (20): (14): (7):
TNF-α 1.60 1.69 1.69 1.07 F(2,48) = 0.05, p = 0.95
0.78 0.72 0.68 0.26
(N): (19): (19): (14): (7):
IFN-γ * 4.07 3.17 2.08 0.92 *F(2,42) = 3.54, p = 0.038, η2 = 0.14
2.37 1.76 0.96 0.20
(N): (16): (18): (12): (5):
IL-16 140.23 135.18 135.90 123.92 F(2,50) = 0.08 p = 0.92
35.36 28.35 57.10 43.51
(N): (19): (21): (14): (7):
IL-10 1.08 1.04 0.75 0.91 F(2,48) = 0.77, p = 0.47
0.64 0.75 0.44 0.66
(N): (18): (21): (13): (4):
IL-13* 7.42 5.92 5.86 4.03 *F(2,31) = 2.89, p = 0.07, η2 = 0.16
2.95 2.22 1.55 1.29
(N): (14): (11): (10): (3):
The ANCOVA covariate was age: analyses excluded SIBS: see text for one-way analyses. Cytokines with proinflammatory activity include IL-1β, 
IL-2, IL-6, TNF-α, and IFN-γ and with antiinflammatory activity include IL-10 and IL-13. Both properties have been ascribed to IL-16 in different 
disorders.
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ratios reflected sensitivity to allergy and were associated
with S100B levels and oppositional symptoms. While
associations between some interleukins were maintained
across groups (e.g. TNF-α, IFN-γ, IL-13), a potential
homeostatic imbalance for others (IL-2, IL-6, IL-10) is
evident from group specific relationships.
Discussion
The principle results of this study may be summarised as
follows.
1/S100B
a) There were no group differences for levels of S100B
(ADHD ± medication):
b) In general, S100B levels were positively related to
anxiety, but in ADHD children (controlling for oppo-
sitional behaviour) the relationship of lower S100B
levels with anxiety was negative
c) Decreasing S100B levels in ADHD groups related
to decreasing levels of IL-16, but increasing levels IL-
10 (independent of age), - where IL-16 and IL-10 cor-
related with allergy sensitivity. IL-16 relationship to
oppositional/hyperactive symptoms depended partly
on allergy sensitivity.
2/Interleukins
a) There were no clear group difference for interleu-
kin levels or ratios of pro/anti-inflammatory interleu-
kins
b) Psychostimulant medication tended to normalise
the slightly altered levels of pro-and anti-inflamma-
tory interleukins and significantly increased some
pro/anti-inflammatory interleukin ratios
c) Common to each group were associations between
TNF-α, IFN-γ and IL-13, suggesting intact control
systems. But relations of TNF-α and IFN-γ to IL-2
and IL-6 to IL-10 were specific to ADHD, ADHDmed
and controls, respectively, suggesting condition/state-
dependent influences in the 3 groups.
3/Amino acids and kynurenine metabolism
a) Tryptophan availability was moderately increased
in both ADHD groups over control values.
b) A strong association of kynurenine to its toxic
metabolite 3HK exclusively in controls contrasted
with modest associations for neuroprotective indices
in all groups
c) Medication moderated the production of 3KA in
the ADHDmed group.
d) Amino acid levels and their group-specific associa-
tions with 3HK support marked catabolic activity that
may indicate neural pruning activity in controls
rather than ADHD children.
S100B
Our main hypothesis of altered serum levels of S100B in
ADHD was not upheld. A trend towards lower levels of
this putative biomarker of astrocyte integrity in patients
with symptoms of anxiety, disturbed mood and poor self-
esteem could indicate an inefficient energy supply to sup-
port active neuronal function in a subgroup of children
without conduct problems. This decrease was partly pre-
dicted by the original hypothesis [6,19] and on the
grounds that ADHD is very different from the severe dis-
orders that give rise to increased S100B secretion (see
introduction).
The failure of this first test of impaired astrocyte func-
tion across the whole group of ADHD children has not
disproved hypothesis-1. First, synthesis of S100B is not
unique to astrocytes [8]. Alterations of function relevant
to neuronal support could be masked by other sources of
S100B production. Second, other factors indicative of
astrocyte function should be measured. One example is
LIF, a cytokine released from astrocytes by the ATP asso-
ciated with firing neurons, that is involved in protecting
the neuronal energy supply and in the development of
astrocytes and oligodendrocytes [45,46]. LIF is crucial to
the development of midbrain dopaminergic (DA) cells
[47] relevant to ADHD, a putatively hypodopaminergic
disorder. Unfortunately the analysis here proved insensi-
tive to LIF levels in circulation. Measures of the neuronal
and glial metabolite myo-inositol (MI) should be encour-
aged. MI is crucial to triggering calcium release, an inte-
gral feature of glial signalling. Magneto-resonance
spectroscopic (MRS) studies of infants born prematurely
or at term, at risk for intrauterine insufficiency, have
shown clearly that MI provides an excellent marker of the
appropriate maturation of cerebral structures [48] where
Figure 2 The solid arrows illustrate the significant Pearson corre-
lations between interleukin concentrations in ADHD, ADHDmed 
and Control groups of children and the broken arrows illustrate 
relationships specific to each group identified on the arrow.
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studies of ADHD children describe associations of MI/
creatine ratios with learning, memory and language func-
tion [49] and increases of the glutamate/MI ratio that are
consistent with an inadequate supply of MI [50]. Altera-
tions are evident in several psychiatric disorders with MI
decreases recorded in depressed patients [51] and
increases in those with schizophrenia that correlated with
increases of S100B [9].
Tryptophan metabolism
The neuromodulator 5-HT, for which tryptophan is a
precursor, has become a major focus of interest in
ADHD. Relatively speaking levels of the metabolite 5-
HIAA excreted are often higher than for DA metabolites
and negatively related to measures of signal detection and
attention [21,23,52]. Interactions of 5-HT with the DA
system in impulsivity [53], the sensitivity to expressed
emotion [54] and other functional domains in ADHD
have been reported [22]. The course of development and
differentiation of the CNS is crucially influenced by 5-HT
systems [55,56]. In the present study despite finding
modestly elevated levels of tryptophan, tryptophan avail-
ability and reduced breakdown in ADHD children, we
recorded no group differences for the metabolite 5-HIAA
or kynurenine. Any differences of central origin may have
been masked by unaltered peripheral sources. However,
in each group tryptophan levels correlated with kynure-
nine, which in turn related to KA levels. This is consistent
with the kynurenine pathway being the main metabolic
route for tryptophan [20] that results in protective (KA)
or potentially toxic metabolites (3HK and quinolinic
acid).
KA is an NMDA antagonist mostly of glial provenance.
In the nanomolar concentrations found in the mamma-
lian brain it reduces glutamate induced excitotoxicity that
often results from insult (e.g. hypoxia). As KA is also an
antagonist of α7 nicotinic cholinergic binding sites [57],
reduced KA levels can lead to increased mesocortical
acetylcholine release. In the presence of low levels
increased neostriatal and mesocortical DA release have
been described [58] as being modulated by the α7 nico-
tinic receptor [59]. These features of low levels of KA
could benefit ADHD subjects with cognitive impairment
and a hypodopaminergic system. Against this back-
ground it is notable that the KA levels recorded here were
quite similar between groups and were modestly corre-
lated with other metabolic measures (amino acids).
Striking was a marked association of kynurenine with
3HK levels in the controls, that was absent in the ADHD
groups. The implication of enhanced catabolic processes
in controls was supported by the amino acid analysis. The
levels of 6 amino acids correlated with kynurenine and
3HK exclusively in controls, whereas the ADHD group
showed merely two associations with the neuroprotective
index. The absence of a predominant metabolic direction
in the ADHD group was not altered by medication, but
became ordered to the extent that numerous amino acid
levels related to kynurenine production and the trypto-
phan-breakdown index.
These results suggest that toxic metabolites are not
influencing CNS function in young ADHD subjects, or
alternatively the energy supply through NAD as a metab-
olite of 3HK, was available to healthy children, but
restricted in ADHD [60]. The first of these two alterna-
tives is the opposite of the prediction from hypothesis-2.
We tentatively propose that the normal process of reduc-
ing and pruning neuronal processes and synapses in late
childhood [61,62] was proceeding in the healthy more
than in the ADHD children. This supports descriptions of
delayed maturation in ADHD [63,64]. Future study
should determine whether the alternative of a restricted
NAD supply in ADHD is pertinent. Certainly, the
absence of differences in the levels of branched-chain
amino acids circulating between diagnostic groups sug-
gests that these are not providing a supplemental source
of energy for ADHD or typically developing children
[36,37].
In the presence of pathology one would expect an
increase in the tryptophan breakdown index (kynure-
nine/tryptophan) associated with an upregulation of
proinflammatory IFN-γ and TNF-α that modulate the
activity of the enzyme IDO [65]. Compared to controls,
the present results for ADHD showed a reduced break-
down index, equivocal changes in TNF-α and only an
upregulation for IFN-γ. This latter result merits attention
in future study as there were decreases of IFN-γ levels
and the IFN-γ/IL-13 ratios in the ADHD group on medi-
cation.
Cytokines
The idea to study selected interleukins came from reports
of their influence on tryptophan metabolism [27]. As they
can cross the blood brain barrier [66-68], immunological
influences on brain function are likely and peripheral
measures relevant. Pro-inflammatory interleukins influ-
ence synaptic plasticity, neurogenesis and neuromodula-
tion [69]. Potentially relevant to ADHD, for example, is
that IL-2 can modulate the development of nigrostriatal
and mesolimbic DA systems [70], enhance NA utilization
[71], and like IL-6 influence reaction times and working
memory performance [72,73]. IL-1β is able to directly
influence signalling between brain regions [74] and has
been related to the development of hostility-related traits
relevant to oppositionality even in healthy subjects [75].
In animal models low/high levels of IL-1β result in
decreases/increases of 5-HIAA [76]. Proinflammatory
interleukins (including IL-6 and TNF-α) can enhance glu-
tamate receptor activation and inhibit GABA and glycine
responses [77]. While normal physiological levels of IL-6
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induced toxicity, elevated levels and toxicity can arise
under conditions of hypoxia and brain damage, and are
seen in a number of brain disorders [78,79]. Along with
TNF-α, these proinflammatory cytokines can mediate
the effects of stress on monoamine activity and cognitive
performance [80,81]. Many of these effects may be medi-
ated by neurons, but many may occur via the astrocytes,
the control of energy supply and glutamate activity [82].
Antiinflammatory cytokines (e.g. IL-10) can counteract a
number of these physiological and cognitive effects
[83,84]. As yet there has been no study of the potential
relevance of these effects to the development and expres-
sion of the features of ADHD.
Of the 8 interleukins measured, 6 showed a marginal
increase in the ADHD group. IL-1β levels showed a small
decrease. These measures all tended to be corrected in
the ADHDmed group. These trends reached borderline
significance for IFN-γ and IL-13. Hirschberg et al. [85]
observed that following an insult on brain function a
degree of inflammation is essential for regeneration, and
in this case a small antiinflammatory response was
observed. The small size of the effect may reflect its insig-
nificance or that the levels measured were a small echo of
what may have been shown earlier in development
around the onset of the disorder [43]. It is worth noting
that no relationship with allergy sensitivity was recorded.
The ratios of pro- to antiinflammatory cytokines did
not distinguish ADHD cases from controls (hypothesis -
3), and thus there is no evidence for an imbalance that
would affect the induction of the enzymes (IDO and
TDO). This contrasts with findings of elevated proin-
flammatory cytokines from adults suffering from depres-
sion [27,86] and melancholia [87]. However, low levels of
the ratios of IL-1β to antiinflammatory cytokines in the
ADHD group were higher in the medicated group. We
would propose that the tendency of medication to 'norm-
alise' interleukin levels does not reflect the well-known
blockade of psychostimulants of the neuronal DA trans-
porter, but rather their ability to stimulate the energy
transfer functions of astrocytes [88]. This refers in partic-
ular to the uptake of circulating glucose, its transfer and
utilization as lactate by neurons, or storage as glycogen in
the glial cells for the supply of energy when required
[89,90]. This mechanism is an important component of
the hypothesis to explain variability in ADHD [6].
Lastly, the role of the pro-/antiinflammatory IL-16
cytokine is worthy of further study. In a genome wide
scan of ADHD subjects [34], 2 SNPs were associated with
the inattentive phenotype. While IL-16 levels did not dif-
fer between the groups studied, they correlated positively
and IL-10 levels correlated negatively with the experience
of allergy across all subjects: (see [91] on low IL-10 trans-
mission reflecting paternal allergy). Exactly paralleling
this were similar correlations with S100B. Indeed, within
ADHD IL-16 levels correlated with ratings of opposi-
tional behaviour. The production of IL-16 has been asso-
ciated previously with asthma, and its secretion to
depend on stimulation by 5-HT via 5-HT2a receptors
[92]. IL-16 can also stimulate the production of IL-1β, IL-
6 and TNF-α in monocytes [93]. The prevalence of aller-
gic sensitivity has long been reported to be higher in
hyperactive children [94,95] and that symptoms can be
alleviated by removal of allergens [96]. Indeed, allergies
may be over twice as frequent among ADHD children
with internalizing problems as healthy children, or those
with ADHD and comorbid conduct disorder [97]. This
supports the association with S100B described above.
Limitations
The principle limitations in this study relate to the small
number of subjects in each group, that in turn limits the
power of the analyses. The number of sibling controls
volunteering to participate was also smaller than antici-
pated. It was necessary to control for an imbalance in
gender and age in the analyses. This arose through the
difficulty of persuading children to provide samples for
research rather than clinical reasons. Technical difficul-
ties in the biochemical analyses further reduced the num-
ber of data for some measures. However, the study was
intentionally preliminary and the aims entirely explor-
atory without conservative correction, to see if there were
any indications of alterations in the levels of potentially
relevant cytokines that merited a follow-up with an
intensive study. Further, an interpretation of the effects of
medication is limited by the cross-sectional between-
group design of the study. It would be preferable for a
future in-depth study to employ a longitudinal within-
subject design.
Conclusions
Over the last 10 years it has become recognized that
inflammation may represent a common mechanism of
neuropsychiatric disorders as well as somatic disease (e.g.
depression, schizophrenia, and dementia). In the brain
this can be represented by excitotoxicity and impairment
of glial function. We show here that one marker of glial
function (S100B) is not dysfunctional across the major
manifestations of ADHD, even though its activity may be
low in those with internalizing comorbidities. We also
show that there is no major dysfunction in the balance of
pro- and anti-inflammatory interleukins that modulate
the production of toxic and protective kynurenine-
related metabolites of tryptophan. However, the results
do show a certain disorder of catabolism that together
may influence features of ADHD (e.g. oppositional char-
acteristics). Nonetheless, there were two stronger find-
ings. The first is that toxic kynurenine metabolites are a
feature of late healthy childhood and this may point to the
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widely reported in normal development. The second is
that there is a normalising influence of psychostimulant
medication on immunological characteristics that points
to a widely neglected locus of pharmacotherapeutic
action, namely glial function. This parallels previously
documented actions of antidepressant therapy [98].
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